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Background: Neoadjuvant chemotherapy (NACT) provides a survival advantage in
breast cancer. Prior to mastectomy, NACT shrinks tumor size and improves pathological
response in breast cancer. Evidence to date has evaluated the impact of chemotherapy on
autologous breast reconstruction outcomes as a binary variable. In this study, we evaluate
the effect of specific NACT regimens and dosage on rate of post-operative complications
after autologous breast reconstruction. We also evaluate the effect of NACT on
circulating immune cells that orchestrates wound healing.
Methods: Following IRB approval, patients who underwent NACT and microvascular
breast reconstruction at Yale New Haven Hospital between 2013 and 2018 were
identified. Demographic variables, oncologic history, chemotherapy regimens, and
complication profiles were abstracted from the electronic medical record. Chemotherapy
regimens were stratified by inclusion of anthracycline and order of taxane. Statistical
analysis identified significantly varying factors between complication and no-

complication cohorts. Chi-squared tests, Fischer exact tests, and t-tests were used for
univariate analysis. Multivariate binary logistic regression was used to control for
confounding variables.
Results: 100 patients met inclusion criteria. In a multivariate regression model
controlling for significant covariates like BMI and ASA, the administration of taxanefirst in an anthracycline-containing chemotherapy regimen was associated with increased
complications (OR = 3.521, p = 0.012). In particular the administration of taxane-first
was associated with a 2.5-fold increase in incidence of fat necrosis (OR = 2.481, p =
0.040). Logistic regression model evaluating the effect of taxane-first regimen on
complication rates, the AUC was estimated to be 0.760 (p < 0.0001), particularly fat
necrosis 0.635 (p < 0.05). There was no correlation between anthracycline inclusion and
postoperative outcomes. The dosage of chemotherapy, the number of days between
NACT completion and surgery, and the number of circulating immune cells did not have
a significant effect on postoperative outcomes.
Conclusion: The administration of taxane first in an anthracycline-containing NACT
regimen contributes to an increase in minor postoperative autologous breast
reconstruction complications. particularly fat necrosis. Our report has the potential to
inform the sequence of NACT administration but the benefits of taxane-first regimens in
improving tumor outcome may outweigh increased post-reconstruction complication risk.
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1
INTRODUCTION TO THESIS

Breast cancer, excluding non-melanoma skin cancer, remains the leading cancer
diagnosis in females around the world. In 2019, there was an estimated 268, 600
diagnoses in the United States, representing 30% of new cancer cases in women. Of this,
41,760 cases accounted for breast cancer deaths in the United States2. Despite advances
in several non-surgical treatment approaches such as targeted immune and hormone
therapies, chemotherapy and radiation; nearly 40% of patients require mastectomy of the
diseased and often contralateral breast3. Extirpative surgery in the absence of
reconstruction can lead to altered body image that impacts on sexual and psychosocial
well-being4. Breast reconstruction impacts positively on a patient’s psychosocial wellbeing5. Autologous breast reconstruction, performed using either pedicled or
microvascular approaches, uses patient’s own tissue and offers the advantage of a more
long-lasting, natural-feeling breast6.

Neoadjuvant chemotherapy (NACT) offers the advantage of reducing tumor
burden and improving pathologic response 7-10. NACT potentially offers a predictive
value of long-term survival based on treatment response11. Indications for NACT have
expanded to include treatment of early-stage and locally advanced breast cancer,
irrespective of tumor size12. Just as autologous breast reconstruction has evolved from
pedicled to microvascular to perforator flaps, neoadjuvant therapy has evolved as
evidence has linked efficacy to the specific NACT regimen13.
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Reconstructive outcomes, in theory, may be affected adversely by the cytotoxicity
of preoperative chemotherapy14-18. Several studies have explored the postoperative effects
of NACT on overall oncological outcomes and more specifically, on breast
reconstruction 14-16,18-22. There are conflicting data on the actual effects of NACT on post
reconstructive outcomes. Some studies report that NACT is significantly associated with
minor post-operative complications among patients receiving NACT compared to those
who did not15,20,21 while others report no similar major and minor postoperative
complication in both group14,16,18.

Previous studies are limited because they did not evaluate the effect of specific
regimens, the sequence of chemotherapy administration, NACT doses, and time between
the last dose of chemotherapy and breast reconstruction operation. Moreover none of
these studies considered the amount of circulating immune cells that are critical to wound
healing after mastectomy and breast reconstruction19,23. This thesis aims to close these
gaps in literature.
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BACKGROUND

Breast Cancer: Epidemiology, Risk factors and Pathophysiology

Breast cancer is the most commonly diagnosed cancer worldwide and continues
to be the leading cause of cancer mortality in women. In the United States, there is a
projected incidence of 281,550 cases in 202124. 1 in 9 women will develop breast cancer
in their lifetime with peak incidence among 60 – 69 year old age group2. Age and female
sex are the most common risk factors. Others include early menarche, late menopause,
nulliparity, late age at first full-term pregnancy, and having a personal prior and/or family
history of breast cancer25. About 20% of breast cancers worldwide can be attributed to
modifiable risk factors including obesity, physical inactivity and alcohol use26.
Approximately, 5 – 10% of breast cancer cases are hereditary and are largely attributed to
BRCA gene mutations. BRCA gene mutations are most commonly found in persons of
Ashkenazi ancestry. The risk of developing breast cancer increases to 60 – 85% with
presence of BRCA-1 and BRCA-2 mutations27.

The pathology of breast cancer typically arises from hyperplasia of epithelial cells
from the breast ducts or lobules and eventually progresses to invasive carcinoma. Less
commonly, invasive breast carcinoma such as angiosarcoma, primary stromal sarcomas
and phyllodes also arise from nonepithelial cells of the supporting stroma. The exact
mechanism that initiates this hyperplasia is unknown, however, similar to other solid
tumors. It has been proposed that the genetic mutations that lead to gain or loss of
function of certain genes may be responsible. TP53, a tumor suppressor gene is the most
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commonly mutated gene28. Its repression has been seen in 41% of tumors. Mutation of
genes in the family of cyclin D1, a cell cycle regulator has been shown to sustain the
proliferation of tumor cells. Other frequently mutated genes that have been reported in
early breast cancers include PIK3CA (30%), MYC (20%), PTEN (16%), CCND1 (16%),
ERBB2 (13%), FGFR1(11%, and GATA3 (10%)28.

The most common subtype of breast carcinoma is ductal carcinoma in situ (DCIS)
which represents about 85% of carcinoma in situ. DCIS usually presents as
microcalcifications that are detectable on mammography and typically involve a focal
small area in one breast. In contrast, lobular carcinoma in situ (LCIS) arises from the
lobules of the breast and is typically multifocal and bilateral. LCIS does not form
microcalcifications making mammographic detection challenging. Both DCIS and LCIS
highly increase the risk for developing invasive carcinoma25. Invasive carcinoma is most
commonly adenocarcinoma, 80% originates from infiltrating ductal type. Other
histological variants include lobular carcinoma, rarely, medullary carcinoma which
accounts for 6% of invasive cancer, papillary, tubular, and mucinous or colloid
carcinoma. Inflammatory breast cancer is an aggressive, fatal cancer as it spreads rapidly
to the lymph nodes24.

Breast cancer can also be classified based on immunohistochemistry or presence
of receptors on the surface, cytoplasm or nucleus of breast cancer cells. The most
common nuclear hormone receptor is estrogen receptor (ER) and progesterone receptor
(PR). HER2, is a receptor tyrosine-protein kinase surface receptor and member of the
human epidermal growth factor receptor family. The over-expression and amplification
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of HER2 has been shown to play a significant role in the development of breast cancer.
Expression of HER2 is generally a risk factor for more aggressive cancer while estrogen
and/progesterone positive breast cancer usually have a more favorable prognosis 29.

Breast cancer: Screening, Diagnosis and Management

There is an increased rate of breast cancer diagnosis in the recent decade,
however, the survival rate has greatly improved most likely due to timely detection of the
disease. Early detection of breast cancer is crucial to survival as the process from
hyperplasia to invasive cancer typically occurs over 10 – 20 years. Mammography which
detects microcalcifications is the most widely used screening tool for detection of breast
cancer. The U.S. Preventative Services Force recommends biannual screening
mammography for women aged 50 to 74 years30. Other screening tools include Magnetic
Resonance Imaging (MRI), ultrasonography, and digital breast tomosynthesis.
Particularly, breast MRI and digital tomosynthesis is recommended to women with dense
breasts, those presenting with lobular carcinoma and women 30 years and above with
high risk of developing breast cancer31. This includes women with known or suspected
BRCA gene mutations, significant family history, and previous exposure to mantle
radiation to the chest. While MRI is more sensitive for detection of breast cancer, its high
cost and low specificity makes mammography a more universal tool for breast cancer
screening. Ultrasonography is not recommended for surveillance of breast cancer.
Currently, self-breast examination has not been shown to reduce breast cancer mortality
or increase detection of cancer between recommended screening mammography 32. A
study evaluating the utility of using ultrasound in addition to screening mammography in

6
women with elevated risk for breast cancer showed that although ultrasound plus
mammography increased the diagnostic yield (from 8 to 12 per 1000 women, 95% CI
1.1-7.2) there was also an increased rate of false positive results therefore, lowering the
positive predictive value33.

The management of breast cancer often involves a multidisciplinary approach
including medical, radiation, and surgical oncology depending on the stage of the disease.
Image-guided core biopsy is required for definite diagnosis of breast cancer. Axillary
ultrasound is used to screen for spread to lymph nodes. Estrogen, progesterone and HER2
have become important therapeutic targets and biomarkers for breast cancer34. Therefore,
assessment of the presence of biomarkers such as ER, PR and HER2 via
immunohistochemistry is required for all patients with invasive breast cancer. In ER+
breast cancer, the blockade of estrogen to the estrogen receptor is targeted most
commonly with tamoxifen which acts as an estrogen antagonist in breast cells but an
estrogen agonist in other tissues like the uterus and the bone. Raloxifene is a selective
estrogen receptor modulator that acts similarly to tamoxifen except it has the additional
benefit of being an estrogen antagonist in the uterus making it a suitable therapy for postmenopausal women at increased risk for developing uterine cancer. Aromatase inhibitors
that prevent production of estrogen are also used in some subset of patients. The use of
aromatase inhibitors over a period of 5 years have been shown to reduce breast cancer
mortality by 15% compared to tamoxifen only35. Ultimately, the patient’s clinical factors
including risk of relapse, bone health, preference, and tolerability of side effects should
be used to determine the agent of choice. HER2+ breast cancer is treated with
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monoclonal antibody, Transtuzumab. Transtuzumab induces an immune-mediated
response that downregulates HER2, thus reducing the division of cancer cells.

The histological and ultrasound information along with clinical assessment are
used to determine the stage of disease and used to guide patient management36. The TNM
staging system of the American Joint Committee on Cancer uses both clinical and
pathological information to suggest the prognosis of patients with cancer37. Patients are
classified into different groups depending on the number and location of primary tumors
(T), involvement of axillary lymph nodes (N), and distant metastasis (M) combine to
make up stages 0 to IV (Table 1)36,38. In addition to determining stage, some pathological
report also include clinical (c) and pathological (p) grading to indicate that a patient has
locally recurring disease or systemic neoadjuvant or adjuvant therapy (y).
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Primary Tumor (T)
TX

Primary tumor cannot be assessed

T0

No evidence of primary tumor

Tis

Carcinoma in situ, intraductal carcinoma, lobular carcinoma in situ

T1

Tumor ≤ 2 cm in greatest dimension

T1a

Tumor > 0.1 cm but ≤ 0.5 cm in greatest dimension

T1b

Tumor > 0.5 cm but ≤ 1cm in greatest dimension

T1c

Tumor > 1 cm but ≤ 2 cm in greatest dimension

T2

Tumor > 2 cm but ≤ 5 cm in greatest dimension

T3

Tumor 5 cm in greatest dimension

T4

Tumor of any size with direct extension to chest wall or skin only

T4a

Extension to chest wall

T4b

Edema or ulceration of the skin of the breast or satellite skin nodules confined to the same breast

T4c

Both T4a and T4b

T4d

Inflammatory carcinoma

Regional Lymph Nodes (N)
NX

Regional lymph nodes cannot be assessed

N0

No regional lymph node metastasis

N1

Metastases in one to three axillary lymph nodes and/or internal mammary nodes with metastases detected by SLN biopsy

N1a

Metastasis in one to three axillary lymph nodes, at least one metastasis greater than 2.0 nun

N1b

Metastasis in internal mammary nodes detected by SLN biopsy

N1c

Metastasis in one to three axillary lymph nodes and in internal mammary lymph nodes detected by SIN biopsy

N2

Metastasis in four to nine axillary lymph nodes or clinically detected, internal mammary lymph nodes in the absence of
axillary lymph node metastases

N3

Metastases in 10 or more axillary lymph nodes or infraclavicular lymph nodes

Distant Metastasis (M)
MX

Distant metastasis cannot be assessed

M0

No distant metastasis

M1

Distant metastasis, including metastasis to ipsilateral supraclavicular lymph nodes

Table 1: The American Joint Committee on Cancer TNM Staging System of Breast
Cancer. Sentinel Lymph Node (SLN)

9
DCIS is primarily managed surgically either with breast conservation
lumpectomy with or without radiation or total mastectomy. LCIS is treated with surgical
excision to negative margins and adjuvant hormonal therapy such as tamoxifen,
raloxifene, or aromatase inhibitors to reduce risk of tumor recurrence or progression of
disease to invasive carcinoma. Early breast cancer contained within the breast and free of
spread to the axillary lymph nodes is curable while metastatic disease is not. Stage 1 and
II disease are considered early disease and managed with a combination of neoadjuvant
chemotherapy, breast conservation surgery or mastectomy, and adjuvant radiation
therapy and hormonal systemic therapy in a subset of hormone or epithelial growth factor
positive breast cancer. Stage III disease also known as locally advanced disease is treated
more aggressively with neoadjuvant systemic chemotherapy, total mastectomy and lymph
node removal followed by radiation and hormone therapy. Given that stage IV disease is
incurable, symptom management in attempt to prolong survival and improve quality of
life with systemic chemotherapy, hormonal therapy, and radiation therapy is the main
goal of the management36.

Neoadjuvant Chemotherapy

Neoadjuvant chemotherapy (NACT) is used to describe chemotherapy given
before surgery to reduce tumor size and increase the rate of breast conserving therapy.
Historically, NACT has been used to treat early stage and locally advanced cancer,
including inoperable and inflammatory breast cancers39. There are several advantages to
use of NACT in locally advanced breast cancer treatment including reduction of tumor
progression prior to surgery, decreased rate of cross-resistance to other chemotherapies,
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and decrease in operation-related morbidity. NACT is associated with higher disease-free
state and overall survival. Previous studies have shown that there is a direct correlation
between an increased number of axillary lymph node metastases and worse overall
prognosis without NACT when patients with similar nodal statuses were compare40.
Additionally, it has been demonstrated that NACT downstages stage II/IIIA breast
cancer, allowing for a cosmetically acceptable surgical approach. The overall response
rate in each of the seven trials assessed was approximately 60 – 90% rate40. Other studies
have shown a pathological complete response rate between 12 – 50% depending on
characteristics of the tumor41. The efficacy of NACT is based on the type of regimen
used. The individual regimen is determined based on molecular subtype, degree of tumor
burden and risk of cancer recurrence. Currently, standard chemotherapy regimens for
HER2- breast cancer include an anthracycline and a taxane given in sequence to reduce
toxicity. Other agents like cyclophosphamide, carboplatin, methotrexate and/or
fluorouracil are sometimes included in the regimen.

Anthracyclines: Mechanism of Action and Toxicity

Anthracyclines is a class of drugs extracted from the Streptomyces bacterium.
They remain one the most effective chemotherapeutic agents used to treat several
cancers42. The most important anthracyclines include doxorubicin, daunorubicin,
epirubicin, and idarubicin with doxorubicin being the most commonly used agent in
modern area42. Anthracyclines induce cytotoxicity and tumor killing by intercalating
between DNA base pairs and inhibiting the activity of DNA topoisomerase II 43. As such,
the drug inhibits DNA and RNA synthesis and blocks cell division especially in highly
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replicating cells like breast cancer cells. The bulky 4-ring structure of anthracyclines - a
tetracycline molecule with anthraquinone backbone connected by a glyosidic linkage
makes the intercalation between DNA base pairs effective. It has also being suggested
that the quinone moiety of anthracyclines generate reactive oxidative species that result in
oxidative stress which damages DNA and triggers cell apoptosis 43.

Although the mechanism of action of anthracycline makes it a very effective
cytotoxic agent, the lack of specificity limits its use in humans. The two major side
effects, both of which are dose dependent, include myelosuppression and cardiotoxicity44.
Since the myelosuppression is reversible and can be combatted with therapeutic
cytokines, cardiotoxicity is the major limitation for use of large doses of anthracyclines
especially doxorubicin. Anthracycline-induced cardiotoxicity is dose dependent and
cumulative and can occur both acutely and chronically. Acute toxicity occurs during or
immediately after drug administration and results in aberrant electrical activity of the
heart, hypotension, and vasodilation44,45. Chronic toxicity manifests as dilated
cardiomyopathy, left ventricular dysfunction and eventually congestive heart failure. The
oxidative stress and lipid peroxidation induced by anthracyclines has been implicated as
the cause of the cardiac injury44. Anthracycline have a high affinity for cardiolipin, a
phospholipid present in the mitochondria. This interaction causes cell injury and
apoptosis induced by lipid peroxidation and reactive oxidative stress44. Cardiac tissues
due to the relative high number of mitochondria are particularly susceptible to this
reaction. Furthermore, cardiac tissue have low levels of anti-oxidant enzymes like
catalase and superoxide dismutase limiting their defense mechanism against reactive
oxidative species46. Given that the chronic toxicity of anthracyclines limits the use of
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anthracyclines, several strategies have been attempted to minimize cardiotoxicity. In
practice, there is a set lifetime maximum dose of 400 – 450 mg/m2 recommended to
prevent development of heart failure47. Finally, dexrazoxane is an iron chelating agent
used to increase protection of cardiac tissues.

Taxanes: Mechanism of Action and Toxicity

Taxanes come from the diterpenes class of plants. Taxanes induce cell killing by
disrupting microtubule function that are essential to cell division. By binding to GDPbound tubulin in the microtubule, taxanes prevent the depolymerization of the mitotic
spindle thus inhibiting cell division, trapping the cell cycle in G2 or M phase which
eventually induce cell necrosis48. Docetaxel and paclitaxel are the major
chemotherapeutic taxane agents used in the treatment of breast cancer. Since axonal
degeneration is essential to nerve function, dose dependent neurotoxicity is the main side
effect of taxane use48.

In the treatment of early-stage and locally advanced breast cancer, several studies
have shown that anthracycline-and taxane-containing neoadjuvant chemotherapy
improves the response rate of breast cancer cells when compared to anthracycline-free
neoadjuvant chemotherapy10,49-51. In some patients, anthracycline specifically
doxorubicin is given before taxane, most commonly docetaxel and in others docetaxel is
given before anthracycline. In HER2+ patients, this regimen is often followed with
Transtuzumab. The administration of taxane before anthracycline has been associated
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with improved pathological complete response, from 15% to 20%, compared with
anthracycline-first sequence52.

Breast Cancer Surgery

Surgical removal of the primary tumor remains a primary component of breast
cancer treatment. Traditionally, radical mastectomy with complete removal of the breast
and axillary lymph nodes was the surgical goal, however, over the past decade,
conservation of the breast while maximizing treatment is becoming the mainstay surgical
approach. As discussed above, in early-stage or locally advanced breast cancer, surgery
often follows NACT. The use of NACT to shrink the tumor size makes breast-conserving
surgery possible. In a study by the National Surgical Adjuvant Breast and Bowel Project
(NSABP) randomizing patients with stage I or II disease with tumors less that 4cm to
lumpectomy vs. lumpectomy plus radiation vs. mastectomy, there was no difference in
overall survival between the groups. However, the rate of recurrence was significantly
higher in the lumpectomy group with 39.2% developing disease after 20 years 53.
Ultimately, for tumors less than 5 cm, the decision should be patient-centered.

Mastectomy is the complete removal of breast tissue. Indications include locally
advanced disease greater than 5cm, stage II-IV disease involving axillary lymph nodes or
chest wall, persistent positive margins after breast-conserving surgery or inflammatory
disease. There are several types of mastectomy based on how the surgery is performed
and how much tissue is removed. In skin-sparing mastectomy, the inframammary fold
and as much native skin as possible is preserved, only the breast tissue, nipple and areola
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are removed. This approach is used when immediate breast reconstruction is planned36.
Nipple-sparing mastectomy is very similar to skin-sparing. In this case, the breast tissue
is removed while the breast skin and nipple are preserved. Nipple-sparing mastectomy is
also performed with plans for immediate breast reconstruction. In both skin-sparing and
nipple-spearing mastectomy, the nipple-areolar complex is assessed intraoperatively to
ensure that there is no tumor involvement. In contrast, a simple mastectomy involved the
excision of all breast tissue including the pectoralis major fascia, nipple, areola and
screen with or without removal of axillary lymph nodes. Modified radical mastectomy as
the name suggests is the most aggressive surgical approach, it combines simple
mastectomy with removal of axillary lymph node dissection. It is used to treat higher
stage, more invasive and inflammatory breast cancer 54.

Breast Reconstruction: Implant and Autologous Reconstruction

Immediate breast reconstruction is offered routinely to patients undergoing
nipple-sparing or skin-sparing mastectomy as part of the management of breast cancer.
Immediate breast reconstruction is patient-centered as it significantly reduces the
negative psychological impacts of the body alteration in women who undergo
mastectomy16. Several studies have demonstrated the oncological safety of immediate
breast reconstruction, they found no increase in local or distant recurrence or changes in
disease-free or overall survival in breast cancer patients, even in those with advanced
disease55-58. The goal of breast reconstruction is to create the most naturally-appearing
breast. The two major reconstructive approaches are implant-based and autologous tissue
transfer. Implant-based techniques use prosthesis like silicone or saline while autologous
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tissue technique uses the patient’s tissues. Long-term satisfaction is higher with
autologous reconstruction however, implants offer patients a safe, and less invasive
option.

The use of implants for breast augmentation dates back to 1963 when silicone
implants was first developed by Cronin59. The first attempt to use implant after
mastectomy was in 1971. It usually follows a two-step approach. In the first step, tissue
expanders are placed and gradually expanded until a desired size is reached. The second
stage of the surgery replaces the tissue expander with a breast implant. Nipple
reconstruction and/or mastectomy site revisions can be done at this time or, more
commonly, at another revisionary surgery. Tissue expanders are either smooth versus
textured. Smooth implants are mobile within the implant pocket while textured implants
are immobile and adheres to the pocket60. Implants however, have been associated with
higher surgical site infection rate, unnatural texture, pain associated with elevation of the
underlying serratus muscle/fascia, capsular contracture, and risk of implant rupture. The
complication rates are even higher in patients who undergo subsequent adjuvant
radiation, with re-operation rates as high as 30%61.

Autologous reconstruction uses tissue flaps from different areas of the body.
Tissue flaps can be grouped into pedicle flaps and free flaps. Pedicle flaps are flaps that
can be moved to the breast or chest wall while still being attached to its original blood
supply, meanwhile, free flaps require anastomosis to the blood vessels in the chest wall
for the flap to survive. Compared to implant reconstruction, autologous breast
reconstruction is completely natural and gives a more natural feel. The absence of foreign
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body also reduces the risk for infection and creates more long-lasting results. Finally,
revision of skin defect is easier with autologous reconstruction compared to tissue
expanders. The disadvantages of autologous reconstruction include a more technical and
long-lasting surgery and increased donor site morbidity.

Tissue flaps can be obtained from several sites around the body; however, the
most common reconstruction options are abdomen-based, latissimus dorsi, gluteal and
thigh-based flaps. There are several options for abdomen-based flaps using muscles from
the abdomen. The transverse rectus abdominis myocutaneous (TRAM) flap offers various
advantages. It provides enough soft-tissue bulk for reconstruction of the breast mound.
The TRAM flap can either be pedicled or free. The pedicled TRAM flap receives its
blood supply from the superior epigastric artery tunneled through vessels within the
rectus abdominis muscle. The main complications with this flap are anterior wall hernia
and partial necrosis of the flap60. Free TRAM flaps receive blood supply from the inferior
epigastric vascular pedicle; this allows more freedom for manipulating the tissue for
better reconstructive outcome and minimal risk of necrosis. The deep inferior epigastric
perforator (DIEP) flap is similar to the muscle-sparing free TRAM flap. However, the
transmuscular perforators from the deep inferior epigastric artery perfuse the overlying
skin which minimizes necrosis. Since no muscle is used, donor-site morbidity is also
minimized61. Although DIEP flaps are most commonly used, it has been associated with
higher risk of venous insufficiency, partial flap loss, and fat necrosis62. The latissimus
dorsi flap is another reliable and commonly used flap. It gets robust blood supply from
the thoracodorsal vessels making it advantageous in women at increased risk of wound
complications following implant or TRAM flap reconstruction.
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The potential impact that NACT have on breast reconstruction has been
explored15,16,18-20. The study with the largest sample size by Mehrara et al. demonstrated
that NACT is a predictor of minor post-operative complications particularly increased
infection at the donor site15. Another study by Deutsch et al. revealed a 45% complication
rate in patients who underwent immediate breast reconstruction after receiving NACT19.
In contrast, a study by Abt et al. concluded that immediate reconstruction after NACT did
not result in greater post-operative complication rate but actually reduced the rate of
systemic morbidity following surgery14. Azzawi et al. in a retrospective analysis also had
similar conclusion, they reported that although there was a higher incidence of minor
surgical complications in patients who received NACT, these findings were not
statistically significant16.
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STATEMENT OF PURPOSE

This thesis provides a summary of current breast cancer treatment modalities
including neoadjuvant chemotherapy and mastectomy, and breast reconstruction
techniques. It also examines in details the effects of specific NACT regimen on
microvascular breast reconstruction complication outcomes. Lastly, it details our
investigation on the potential effects of type of neoadjuvant chemotherapy agents,
schedule, number of doses and time between last chemotherapy dose and surgery.

Specific Aims

1. To determine the effect of different anthracycline-taxane containing neoadjuvant
chemotherapy regimens on post-complication outcomes in autologous breast
reconstruction.
2. To provide objective data that informs patient counseling on neoadjuvant
chemotherapy regimen.
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METHODS

Student Contributions

Project question, literature search, chart review, data collection, statistical
analysis, and thesis write-up were completed by the author of this thesis, Olamide
Olawoyin, with contributions from other students including Sumarth Mehta (SM) and
Fouad Chouairi (FC). SM contributed to chart review and data collection. FC provided
advice on statistical analysis and contributed to the patient data base during the early
stages of this project. Dr. Kyle Gabrick wrote the IRB approval and maintained the
database. Dr. Lajos Pusztai provided expert guidance for the medical oncology
component of this project. Dr. Michael Alperovich approved, supervised, and reviewed
all data and thesis write-up.

Ethical Statement

This research was conducted according to the Yale University and Yale NewHaven Hospital ethical guidelines. Institutional Review Board approval was obtained
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Patient Population

We conducted an electronic chart review to identify patients who received
neoadjuvant chemotherapy and immediate autologous breast reconstruction between
2013 and 2018 at the Yale New Haven Hospital. Data collected from the patients’ chart
included age, body mass index, race, stage of breast cancer, prior history of radiation
therapy and abdominal surgery, smoking status, medical comorbidities including
hypertension, diabetes, psychiatric history, American Society of Anesthesiologists score,
and occurrence of minor and/or post-operative complications. The most common
complications recorded were infections, abdominal or other donor-site dehiscence or
necrosis, donor-site infections, partial or complete flap necrosis, abdominal bulge,
operative hernia repair, arterial or venous flap insufficiency, breast hematoma, breast
seroma, fat necrosis, and return to the operating room within 30 days. The incidence of
fat necrosis was confirmed by ultrasound imaging. There were no cases of deep venous
thrombosis / pulmonary embolism, nipple-areola complex necrosis, abdominal
hematoma, or seroma in the cohort.

We also obtained neoadjuvant chemotherapy specific variables such as regimen,
dosage, total length of treatment, and days between completion of chemotherapy and
mastectomy/immediate autologous breast reconstruction. Finally, we collected data for
complete blood count i.e. white blood cell count, absolute white blood cell count,
absolute neutrophil count, absolute leukocyte count, and absolute neutrophil
count/absolute leukocyte count ratio that were recorded at the time of last chemotherapy
dose.
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Details of Neoadjuvant Chemotherapy

We used the National Comprehensive Cancer Network Clinical Practice
Guidelines (Version 4.2018) for Breast Cancer to classify neoadjuvant chemotherapy
protocols. The types of chemotherapy regimen identified from the data set is detailed in
the table below (Table 2).

Regimen

Chemotherapy Content of Regimen (Dosage)

AC + wT

Adriamycin/Cyclophosphamide (every 3 weeks)

CMF

Cyclophosphamide, Methotrexate, Fluorouracil (every 3 weeks)

ddAC

Adriamycin/Cyclophosphamide (every 2 weeks)

ddAC + ddT

Adriamycin/Cyclophosphamide (every 2 weeks) + Paclitaxel (every 2 weeks)

ddAC + wT

Adriamycin/Cyclophosphamide (every 2 weeks) + Paclitaxel (every week)

ddTC

Docetaxel + Cyclophosphamide (every 2 weeks)

EC + wT

Epirubicin/Cyclophosphamide (every 3 weeks) + Paclitaxel (every week)

P

Carboplatin (every 3 weeks)

PwT + ddAC

Carboplatin (every 3 weeks) with Paclitaxel weekly + Adriamycin/Cyclophosphamide (every week)

wT

Paclitaxel (every week)

TC (HP)

Docetaxel/Cyclophosphamide (every 3 weeks), always with Transtuzumab (H) and Pertuzumab (P)

TC + A

Paclitaxel/Cyclophosphamide (every 3 weeks) + Adriamycin (every 2 weeks)

TP

Docetaxel/Carboplatin (every 3 weeks)

wT + CEF

Paclitaxel (every week) + Cyclophosphamide/Epirubicin/Fluorouracil (every 3 weeks)

wT + ddAC

Paclitaxel (every week) + Adriamycin/Cyclophosphamide (every 2 weeks)

wTwP + ddAC

Paclitaxel/Carboplatin (every week) + Adriamycin/Cyclophosphamide (every 2 weeks)

Table 2: Name of Neoadjuvant Chemotherapy Regimen and Content identified from
Patients’ Medical Electronic Records.
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Generally, we grouped chemotherapy regimen based on the inclusion or exclusion of
anthracycline. Grouped as first generation are anthracyline-containing regimens. Second
generation regimen (T-AC) are defined as taxane-containing where taxane is
administered before other agents such as cyclophosphamide and/or anthracycline.
Finally, in third generation regimens (AC-T), administration of anthracycline is followed
by taxane agent.

Statistical Analysis

We excluded patients with incomplete chemotherapy or reconstruction data from
the analysis. Variable were stratified as described above and all statistical analyses were
performed using IBM SPSS Version 25 (IBM Corp., Armonk, N.Y.). To analyze
categorical variables, we performed a univariate analysis with chi-square test. P values
for variables n < 5 are determined by Fisher's exact test, while Pearson's chi-square is
used for variables n > 5. Continuous variables were analyzed using a univariate analysis
with two-tailed t tests. The Shapiro-Wilk test was performed to test whether continuous
variables followed a normal distribution. For continuous variables where a normal
distribution could not be assumed, the Mann-Whitney U test was used to define the pvalue, and the median was evaluated. Descriptive statistics for these variables are
reported as mean ± SD, median, and interquartile range.

We controlled for demographics and comorbidities using a multivariate logistic
regression analysis. Results were reported as frequency or mean ± SD for complication
incidence. Univariate and multivariate p values were included as appropriate.
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Multivariate odds ratios and 95% confidence intervals were reported for all regression
models. We also calculated the areas under the receiver operative curve (ROC) to
investigate the fitting behavior of the logistic regression models used. Statistical
significance was set at p < 0.05 (*p < 0.05, **p < 0.01) for all analyses and areas under
the curve (AUC) greater than 0.6 suggested a high performing logistic regression model.

24
RESULTS
Patient Demographics
In our review, a total of 467 patients underwent autologous breast reconstruction
between 2013 and 2018 at the Yale New Haven Hospital. Of those, 100 patients who
received neoadjuvant chemotherapy and met the inclusion criteria were included in
further analyses. The mean age of those patients was 46.5 ± 9.6 years and mean body
mass index of 30.6 ± 6.2 kg/m2. 64% of patients were non-smokers, 30% were former
smokers, and 6% were current smokers. Complete patient demographics and
comorbidities are presented in Table 3.

Variables

Total

Age, y (mean ± SD)

46.5±9.6

BMI (mean ± SD)

30.6±6.2

Race n (%)
Caucasian n (%)

71 (71%)

Hispanic n (%)

9 (9%)

African American n (%)

14 (14%)

Asian n (%)

3 (3%)

Other n (%)

3 (3%)

ASA n (%)
II

46 (46.5%)

III

53 (53.5%)

Smoking Status n (%)
Current Smoker

6 (6%)

Former Smoker

30 (30%)
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Nonsmoker

64 (64%)

Comorbidities n (%)
Hypertension
Diabetes
Prior Abdominal Surgery

20 (20%)
7 (7%)
51 (51%)

Breast Cancer Stage By Patient n (%)
1

11 (12%)

2

25 (27.2%)

3

17 (18.5%)

3+

17 (18.5%)

Prophylactic and Stage 0 Contralateral breast

39 (42.4%)

History of chest irradiation

4 (4.0%)

Mastectomy Type Per Breast n (%)
Modified Radical

18 (18.8%)

Simple/Skin Sparing

70 (72.9%)

Nipple Sparing (Prophylaxis for Contralateral breast)

8 (8.3%)

Table 3: Demographics, Comorbidities, and Operative Details for Autologous Breast
Reconstruction Cohort.
Body mass index (BMI); American Society of Anesthesiologists (ASA).
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Incidence of Any Complication

The incidence of minor or major complications was 48 out of 100 patients who
met the inclusion criteria. There was no statistical difference in the mean age of patients
with complications vs. those without complications (47.4±10.1 vs. 45.7±9.1, p-value =
0.384). However, the mean BMI of patients with complications was significantly higher
than those without (32.0±7.1 vs. 29.3±5.0 (p-value = 0.029). There was no difference in
the complication rates between former smokers and current smokers (p-value = 0.118).
The presence of comorbidities such as hypertension, diabetes, and psychiatric
comorbidities did not differ significantly between complication rates (Table 4).
Complication rates were higher for patients with high levels of comorbidities, such as
ASA III (70.2% vs. 38.5%; p-value = 0.002). These patients also had a higher rate of 30
day return to the OR (p= 0.019) and higher incidence of complete mastectomy flap
necrosis (p-value = 0.038). We did not observe a significant difference in complication
rate among breast cancer stages or type of mastectomy.

Presence of
Absence of Complications
Demographics by patient

Complications

p-Value
(n=52)

(n=48)
Age, y (mean ± SD)

47.4±10.1

45.7 ± 9.1

0.384

BMI (mean ± SD)

32.0±7.1

29.3±5.0

0.029*

33 (68.8%)

38 (73.1%)

0.637

Hispanic n (%)

4 (8.3%)

5 (9.6%)

1.000

African American n (%)

8 (16.7%)

6 (11.5%)

0.456

Race n (%)
White n (%)
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Asian n (%)

1 (2.1%)

2 (3.8%)

1.000

Other n (%)

2 (4.2%)

1 (1.9%)

0.606

II

14 (29.8%)

32 (61.5%)

0.002**

III

33 (70.2%)

20 (38.5%)

0.002**

Current Smoker

4 (8.3%)

2 (3.8%)

0.423

Former Smoker

18 (37.5%)

12 (23.1%)

0.118

Nonsmoker

26 (54.2%)

38 (73.1%)

0.049*

Hypertension

12 (25%)

8 (15.4%)

0.230

Diabetes

4 (8.3%)

3 (5.8%)

0.707

Psychiatric Diagnosis

8 (16.7%)

6 (11.5%)

0.460

Prior Abdominal Surgery

24 (50%)

27 (51.9%)

0.848

Preop Radiation

2 (4.2%)

2 (3.8%)

1.000

ASA n (%)

Smoking Status n (%)

Comorbidities n (%)

Table 4: Univariate Analysis of Demographics and Comorbidities on Complication Rate
*p < 0.05, **p < 0.01. Significant values are denoted in bold.
Body Mass Index (BMI); American Society of Anesthesiologist (ASA) score.

Oncology and Chemotherapy Regimen

The average time between completion of chemotherapy and surgery was 35.1 ±
12.4 days and there was no time difference between patients with complications and
those without. The average dose of chemotherapy agent was 12.9 ± 4.6 doses. In the
group with complications, there were an average of 13.6±4.5 doses administered while
12.3±4.6 doses were administered in the group without complications (p-value = 0.179).
We did not observe any statistically significant difference between patients’ white blood
cell (WBC), absolute neutrophil count (ANC), absolute lymphocyte count (ALC), or ratio
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of ANC/ALC. In patients with complication, the WBC average was 6.6±2.4 and
ANC/ALC ratio was 3.4±2.0 which was similar to 6.4±2.6 and 5.6±15.9 respectively in
patients without complications (Table 5).

Total (n=100)
PMean(1000/mm3)

Presence of Complications (n =48)

Absence of Complications (n=52)
Value

Q1 – Q3

Mean ± SD

Median

Q1 – Q3

31.0

27.0 – 42.5

70.0 ± 136.8

35.0

29.0 – 46.2

0.119

13.6 ± 4.5

16.0

15.0 – 16.0

12.3 ± 4.6

16.0

8.0 – 16.0

0.179

6.5 ± 2.5

6.6 ± 2.4

6.1

4.8 – 7.9

6.4 ± 2.6

5.8

4.6 – 7.2

0.453

ANC

4.4 ± 2.3

4.3 ± 2.1

3.7

3.0 – 4.8

4.2 ± 2.4

3.3

3.0 – 4.9

0.468

ALC

1.4 ± 0.6

1.4 ± 0.5

1.2

1.0 – 1.7

1.4 ± 0.6

1.4

1.0 – 1.6

0.789

ANC/ALC

4.6 ± 11.7

3.4 ± 2.0

2.8

1.9 – 4.4

5.6 ± 15.9

2.5

1.7 – 3.7

0.362

± SD

Mean ± SD

Median

73.8 ± 143.5

78.0 ± 151.8

12.9 ± 4.6

WBC

Days between last
chemo and surgery
Total Dose
CBC

Table 5: Univariate Analysis of Chemotherapy Outcomes on Complication Rate *p <
0.05, **p < 0.01. Significant values are denoted in bold.
Complete Blood Count (CBC); White Blood Cell (WBC); Absolute Neutrophil Count
(ANC); Absolute Lymphocyte Count (ALC).

Order of Anthracycline and Taxane Administration in Regimen

Of the 100 patients who met inclusion criteria for our study, eighty patients
received NACT with an anthracyline-containing regimen. Seventy-nine of those patients
received two or more agents containing both taxane and anthracycline i.e. 2nd or 3rd
generation regimen. Thirty-four patients were administered taxane first (2nd generation
regimen) and forty-five patients received taxane second in the sequence (3rd generation).
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One patient received only anthracyline and cyclophosphamide and the remaining twenty
patients were administered a single agent of anthracycline only (1st generation).

In general, among the patients who received anthracyline-containing regimen,
forty-one had post-operative complications and thirty-nine had none. In the group of
patients with one or more complications, 43.8% received a taxane-first regimen
compared to 39.6% when taxane was administered second. In contrast, in patients with no
complications, 25% received taxane first while 50% received taxane second in the
sequence. Patients who received taxane first had a statistically significant higher rate of
complication(s) (p-value = 0.048). Hormone therapy did not have any significant impact
on post-operative complications (Table 6).

Total

Presence of

Absence of

(n=100)

Complications

Complications

(n=48)

(n=52)

80 (80%)

41 (85.4%)

39 (75%)

0.193

Single agent Chemotherapy

21 (21%)

8 (16.7%)

13 (25.0%)

0.307

Combination – Taxane second

45 (45%)

19 (39.6%)

26 (50.0%)

0.296

Taxane first - combination

34 (34%)

21 (43.8%)

13 (25.0%)

0.048*

Transtuzumab

40 (40%)

18 (37.5%)

22 (42.3%)

0.624

Pertuzumab

29 (29%)

12 (25%)

17 (32.7%)

0.397

Variables

Anthracycline n (%)

P-Value

Order of Chemotherapy

Hormone Therapy n (%)

Table 6: Univariate Analysis of Chemotherapy Regimen on Complication Rates *p <
0.05, **p < 0.01. Significant values are denoted in bold.
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Stratification of Incidence of One of More Complications

All the patient in our cohort underwent either DIEP or muscle-sparing TRAM
autologous breast reconstruction. Since some patients underwent prophylactic
contralateral breast mastectomy and reconstruction, there was a total of 163 breasts
among the 100 patients in our cohort. We did not observe a statistically significant
difference in incidence of complications between breasts who underwent DIEP flap
reconstruction (n = 137) or muscle-sparing TRAM flaps (n = 26). Post-operative
complication rate also did not differ with number of perforators among breasts. Due to
unrecorded data in some of the patients, we report flap weight for thirty-nine of the 163
breasts. In these breasts, we did not observe a statistically significant difference between
the mean flap weight of breasts with complication (810.3gm ± 456.6gm) compared to
breasts without complications (618.5gm ± 195.1gm), p-value = = 0.183. Furthermore,
post-operative radiation to the flap did not seem to impact complication rate (p-value =
0.309). Fifty-eight breasts underwent post-operative radiation to the flap. We performed
univariate analysis for all covariates described above and detailed in Table 7.
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Total

# of Perforators per flap
Weight of flap (g)

a

n = 139

a

n = 39

Presence of Complications
Mean ± SD (n)
2.2 ± 0.97 (43)
810 ± 456 (17)

Median
2.0
727

Absence of Complications

Q1 – Q3
2.0 – 3.0

Mean ± SD (n)
2.1 ± 0.8 (96)

440 - 956

6 18 ± 195 (22)

Median
2.0
678

Q1 – Q3
2.0 – 3.0
435 - 808

PValue
0.913
0.183

PTotal

Presence of Complications

Absence of Complications

(n = 163)

(n=56)

(n=107)

Value

Type of Flap

0.899

DIEP

137 (84%)

47 (83.9%)

90 (84%)

MS-TRAM

26 (16%)

9 (16%)

17 (15.9%)

Axillary dissection

56 (34.3%)

19 (33.9%)

37 (34.6%)

0.838

Post-op radiation

58 (35.6%)

23 (39.3%)

35 (32.7%)

0.309

Bilateral mastectomy

132 (80.9%)

44 (78.6%)

88 (82.2%)

0.768

Table 7: Univariate Analysis of Flap Covariates on Complication Rate *p < 0.05, **p <
0.01 (by breast) a Total number ( ) differ due to missing data. Significant values are
denoted in bold.
Deep Inferior Epigastric Perforator (DIEP); Muscle-Sparing Transverse Rectus
Abdominis Myocutaneous (MS-TRAM).
We conducted univariate analysis of axillary lymph node dissection in order to
control for any potential effects of invasive or metastatic disease (Table 7). Fifty-six
patients underwent axillary lymph node dissection and there was no significant impact on
rate of post-operative complications among these patients (p-value = 0.838).

We performed a multivariate binary logistic regression analysis to control for
confounding variables such as BMI, ASA, diabetes, post-operative radiation, axillary
lymph node dissection, unilateral vs. bilateral flap reconstruction, DIEP vs. musclesparing TRAM flap, and number of perforators per flap. We observed that higher BMI
was associated with higher rate of complications (p-value = 0.020; odd ratio = 1.185)
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(Table 8). More importantly, we observed a positive statistically significant association
with administration of taxane first and rate of post-operative complications. Patients who
received taxane first had higher rates of complications even after controlling for the
aforementioned potential confounding variables (p-value = 0.012, OR 3.521) (Table 8).

Adverse Effects

OR (95% CI)

p-Value

T – AC

3.521 (1.317 – 9.416)

0.012*

BMI

1.185 (1.019 – 1.245)

0.020*

ASA

1.762 (1.061 – 6.499)

0.037*

Diabetes

1.409 (0.115– 11.650)

0.901

Post – op Radiation

2.667 (0.980 – 7.052)

0.055

Axillary LN Dissection

0.946 (0.331 – 2.472)

0.844

Unilateral vs Bilateral Mastectomy

1.471 (0.384– 4.263)

0.688

DIEP vs MS-TRAM

0.334 (0.086 – 1.307)

0.115

Number of Perforators

1.278 (0.854 – 2.525)

0.165

Table 8: Multivariate Binary Logistic Analysis of Chemotherapy Regimen on
Complication Rates Controlling for BMI, ASA, Post-op Radiation, Axillary LN
Dissection, Microvascular type, Perfusion and number of Perforator. *p < 0.05, **p <
0.01 (by breast). Significant values are denoted in bold.
Taxane – Anthracycline/Cyclophosphamide (T - AC)

Using a logistic regression model to determine the effect of taxane-first therapy
on complication rates, AUC was calculated as 0.760; 95% CI 0.666 - 0.853, p * 0.0001
(Figure 1), which indicates that the model performed well overall (Figure 1). This
suggests that the taxane-first regimen is associated with complications in 76% of cases.
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Figure 1: Receiver operator characteristic curve modeling taxane-first administration as
a predictor of complication event.

Fat Necrosis

Upon further stratification of type of complications, we observed that the
incidence of fat necrosis differed significantly based on sequence of taxane
administration. Univariate analysis showed that 28.3% of flaps in patients administered
taxane first had fat necrosis post-operatively, but only 14.6% when taxane was
administered second in the sequence (p=0.035) (Table 9).
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Variables

Taxane first

Remaining Cohort

(n=34)

(n = 66)

21 (61.8%)

27 (40.9%)

Abdominal Hematoma

0

0

Abdominal Seroma

0

0

Arterial

1 (3.0%)

1 (1.5%)

1.000

Venous

1 (3.0%)

1 (1.5%)

1.000

0

0

Any complication n (%)

p-value

0.048*

Microvascular Complications n(%)

Insufficiency

Donor Site Infection
Abdominal Dehiscence
Dressing Changes
OR Repair

0.356
3 (8.8%)

2 (3%)

0 (0%)

1 (1.5%)

Abdominal Site Necrosis
Dressing Changes

0.770
0 (0%)

1 (1.5%)

1 (2.9%)

2 (3%)

Bulge

3 (8.8%)

1 (1.5%)

0.113

Operative Hernia Repair

3 (8.8%)

1 (1.5%)

0.113

Taxane First

Remaining Cohort

p-value

(n=60)

(n = 103)

0

0

OR Repair

Flap complications n(%)

DVT/PE n (%)
Mastectomy Flap Necrosis n (%)

0.676

Partial

2 (3.3%)

5 (4.9%)

Complete

2 (3.3%)

6 (5.8%)

0

0

17 (28.3%)

15 (14.6%)

0.035*

Infection

3 (3.3%)

2 (1.9%)

0.360

Breast Hematoma

1 (1.6%)

2(1.9%)

1.000

Breast Seroma

1 (1.6%)

3 (2.9%)

1.000

Return to OR in 30days

7 (11.6%)

10 (9.7%)

0.740

NAC Necrosis
Fat Necrosis

Table 9: Univariate Analysis of Order of Taxane Administration on Complication Rates.
*p < 0.05, **p < 0.01. Significant values are denoted in bold.
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On multivariate binary logistic regression controlling for potential confounders,
administration of taxane first was associated with a 2.5-fold increase in the risk of fat
necrosis (p-value = 0.040; OR = 2.481) (Table 10).

Adverse Effects

OR (95% CI)

p-Value

T – AC

2.481 (1.041 – 5.914)

0.040*

BMI

1.019 (0.958 – 1.084)

0.552

Diabetes

0.714 (0.073– 7.036)

0.773

Post – op Radiation

2.457 (0.951 – 6.350)

0.063

Axillary LN Dissection

0.890 (0.343 – 2.307)

0.811

Unilateral vs Bilateral Mastectomy

1.407 (0.458– 4.317)

0.551

DIEP vs TRAM

0.767 (0.236 –2.499)

0.660

Table 10: Multivariate Binary Logistic Analysis of Chemotherapy Regimen on Fat
Necrosis Controlling for BMI, Diabetes, Post-op Radiation, Axillary LN Dissection,
Microvascular type. *p < 0.05, **p < 0.01. Significant values are denoted in bold.

In the logistic regression model evaluating the effect of taxane-first regimen specifically
on fat necrosis, the AUC was estimated to be 0.635; 95% CI 0.514 – 0.756, p < 0.05
(Figure 2), indicating an overall satisfactory model performance. Overall, the AUC
estimates that taxane-first regimen is associated with fat necrosis in 64% of cases.
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Figure 2: Receiver operator characteristic curve modeling taxane-first administration as a
predictor of fat necrosis event.

Furthermore, the diagnosis of fat necrosis was made between 9 and 895 days after
surgery and the median number of days was 129.50 days (Table 11). Patients who
received taxane first and those who did not have statistically significant differences in the
time between surgery and fat necrosis diagnosis (p-value = 0.895). Finally, a total of
five patients with fat necrosis were operated on after confirming the diagnosis on
ultrasound, two of whom had received taxane first and three who had not. The size of the
necrotic fat tissue did not differ between patients who received taxane first (2.54cm ±1.54
cm) when compared to the patients who did not (2.39cm ± 0.98cm), p-value = 0.813
(Table 11).
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PT – AC

Remaining Cohort
Value

Mean ± SD (n)

Median

Q1 – Q3

Mean ± SD (n)

Median

Q1 – Q3

# of perforators

2.4 ± 1.1 (14)

2.00

1.8 – 3.0

2.0 ± 0.9 (11)

2.0

1.0 – 2.0

0.429

Weight of flap (g)

679 ± 536 (6)

440

405 - 909

833 ± 221 (6)

879

656 - 1020

0.077

# of days between surgery and fat necrosis

277 ± 197 (17)

209

147 - 386

361 ± 454 (15)

245

69 - 378

0.895

Size of fat necrosis by ultrasound (cm)

2.5 ± 1.5 (9)

2.0

1.4 – 4.3

2.4 ± 1.0 (6)

2.2

1.6 – 3.3

0.813

Return to OR for Fat Necrosis Removal

2 (5)

-

-

3 (5)

-

-

0.522

Table 11: Univariate Analysis of Fat Necrosis by Order of Taxane. *p < 0.05, **p < 0.01.
Significant values are denoted in bold.

Intraoperative Details

In order to evaluate for adequate perfusion in the flap, indocyanine green imaging
(ICG) was used prior to insetting of the flap by the reconstructive surgery. ICG is a water
soluble cyanine dye that binds to blood proteins such as albumin and lipoprotein. The
spectral properties of ICG in the near infrared range makes it a suitable surrogate marker
for angiography and evaluation of tissue perfusion63,64. It has a peak absorption in serum
between 790 and 805 mm and peak emission at 835 mm allowing for penetration in blood
and improved visualization during surgery63. We recorded ICG for 127 of the 163 flaps
in our study. In addition to using ICG to assess for adequate perfusion, the reconstructive
surgeon also clinically evaluated rate of bleeding during de-epithelization. Poorly
perfusing flaps were not used. Any watershed areas with questionable perfusion were
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debrided on the abdomen before the flap was transferred to the chest. ICG was not used
to assess flap perfusion after microsurgical anastomosis.
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DISCUSSION

Neoadjuvant chemotherapy (NACT) reduces the tumor size and the risk of
axillary metastases. Several controlled trials have shown that NACT have similar
recurrence rates, disease-free, and overall survival rates as adjuvant chemotherapy7,8.
Since NACT shrinks tumor size, the administration offers additional benefit for treatment
of early-stage and locally advanced breast cancer12. By shrinking the tumor size, NACT
makes breast conserving therapy in treatment of advanced breast cancer possible,
allowing for immediate autologous breast reconstruction8-10.

Patients with HER2 negative disease often receive anthracycline-based regimens
i.e. doxorubicin (Adriamycin) or epirubicin and cyclophosphamide, preceded or followed
by a taxane (docetaxel or paclitaxel)65 with Carboplatin also sometimes used. Patients
with contraindications, particularly those with cardiac disease are often offered an
anthracycline-free alternative, which includes taxane and cyclophosphamide or
carboplatin66. A few patients receive cyclophosphamide, methotrexate and fluorouracilbased regimen67. Anthracycline free regimen are termed 1st generation, anthracycline and
taxane containing regimen are 2nd generation and anthracycline, taxane, and hormone
therapies (Transtuzumab and or Pertuzumab) are 3rd generation68. Several studies have
shown the benefit of anthracycline-containing ( 2nd or 3rd generation) over anthracyclinefree (1st generation) regimen in improving tumor response rate10,49-51. A study
demonstrates that the administration of taxane before anthracycline was associated with a
significant improvement in tumor response69. The administration of taxane before
anthracycline was also associated with significant improvement in tumor response69.
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In this study, we took a detailed approach to analyze the effect of neoadjuvant
chemotherapy regimen on post-operative microvascular breast reconstruction outcomes.
For the first time in literature, we report a significant association between administration
of taxane before anthracycline and higher incidence of minor post-operative
complication, specifically fat necrosis both on univariate and multivariate analysis. On
further analysis of types of post-operative complications, we confirm previous findings
that have demonstrated that major complications are infrequent.

Advances made in the surgical techniques of autologous (free flap) breast
reconstruction over the years has significantly reduced donor site morbidities 70. However,
across all options for free flap (Transverse Rectus Abdominis Muscle, Deep Inferior
Epigastric Perforator flap, Superficial Inferior Epigastric Artery flap, Superior Gluteal
Artery Perforator, and Profunda Artery Perforator flap), fat necrosis persist as a minor
complication70. Our finding confirms previous findings that have demonstrated an
association between fat necrosis and neoadjuvant chemotherapy15,20,21. Similar to these
studies, we observed that comorbidities such as affect post-operative outcomes.

Although ASA is not the main focus of this study, this study, like others 71-73,
demonstrate that higher ASA score of III correlates with higher incidence of
perioperative complications. ASA score, based on five classes (I to V) is an assessment of
patient’s overall preoperative health. ASA I indicates a normal healthy patient, II
indicates a patient with mild systemic disease and III indicates a patient with severe
systemic disease74. None of the patients in our study had ASA IV or V which denote a
patient with life-threatening disease74. Administering taxane first remained significantly
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associated with higher complication rate after controlling for ASA as a confounding
variable.
Exploring the mechanism of action of taxane offers an insight into why it may
affect fat necrosis when administered first. Taxanes stabilize the mitotic spindle, inhibit
cell division, and induce necrosis by disrupting the disassembly of microtubules 75.
Taxanes are potentially more potent due to the effect on the tumor microenvironment,
reduced clearance, and their pharmacokinetic interaction with anthracylines 76. Few
studies have explored the effects of the sequence of taxane administration on postoperative outcomes. Earl et al. in their exploration of the role of adding gemcitabine to
paclitaxel and epirubicin, an anthracyline and cyclophosphamide, they demonstrate that
although this NACT combo did not improve the pathological complete response,
sequencing NACT administration so that taxane is received before anthracyclines
improve the pathological response rate defined as absence of invasive cancer in the breast
cancer and axillary lymph nodes69. Shi et al. in their investigation of the effect of
chemotherapy on expression of heat shock protein 27, a protein whose overexpression
leads to anthracyline resistant, report that paclitaxel (a taxane) when given before
doxorubicin (an anthracycline) is more effective at clearing breast cancer cells with high
expression of high shock protein compare with doxorubicin-paclitaxel sequence77.
Furthermore, Taghian et al. report that paclitaxel could enhance anthracycline’s cytotoxic
impact on tumor cells by increasing interstitial fluid pressure and oxygenation within the
tumor microenvironment78. These investigations demonstrate that taxane-first NACT
regimen may potentiate tumor killing. Possibly, the higher potency of taxane-first
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administration increase cytotoxicity to the extent that it ultimately induces necrosis in
normal fatty breast tissue.

Post-operative fat necrosis has also been associated with radiation to the flap in
some studies. However, other studies similar to ours do not find this association.
Mirzabeigi et al. in their investigation of patients undergoing immediate autologous
breast reconstruction and adjuvant radiation found a higher incidence of fat necrosis in
irradiated patients79. Garvey et al. also reports similar findings, concluding that radiation
after DIEP and MS-TRAM based breast reconstructions had higher rates of flap
necrosis80. In contrast, Clarke-Pearson et al. reported no clinically significant fat necrosis
observed in either irradiated or nonirradiated DIEP flaps undergone during the immediate
DIEP reconstruction between 2009 and 201181. An additional retrospective study of 183
patients undergoing immediate flap reconstructions by Crisera et al. found that
postoperative radiation therapy did not predict fat necrosis82. According to Taghizadeh et
al. and Kronowitz, this discrepancy may be due to the timing of breast reconstruction83.
The relatively small size of our study may have also contributed to this discrepancy.

Furthermore, we show that dosage, the time interval between completion of
NACT and surgery, and complete blood count do not affect post-operative outcomes.
This was unexpected since taxane and anthracycline have been shown to affect the
immunological health of the patient. In fact, one of the most devastating side effects of
anthracyclines is myelosuppression and neutropenia due to cytotoxicity to the bone
marrow44. The effect of NACT on blood cell count was important to explore because
NACT has been shown to delay wound healing especially when administered two weeks
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prior to surgery19. Absolute neutrophil count (ANC) less 500 cells/mm3 have been shown
clinically to lead to worse wound healing outcomes84. The institutional protocol at YaleNew Haven Hospital for this cohort has been to delay surgery until ANC recovers and is
above 1.0 cells x 1000/mm3. The higher ANC of the patients in our study before surgery
possibly explains why we observed no significant post-operative wound healing
complications.

The limitations of this study include a small sample size. We were underpowered
to detect differences in complications based on each NACT regimen. Missing data in the
electronic medical records of some patients in our database led to a small sample size.
This also prevented us from doing more detailed analysis of the effect of factors like
number of perforators used and flap perfusion prior to inset. In addition, as our study is a
retrospective study, a prospective randomized case-controlled study needs to be done to
confirm our claim. Despite these limitations, we were able to reveal that the sequence of
anthracycline-containing NACT regimen plays a role, albeit, minor in the post-operative
complication rate of microvascular breast reconstruction.
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CONCLUSION

The administration of taxane first in an anthracycline-containing NACT regimen
contributes to minor post-operative autologous breast reconstruction complications.
Specifically, taxane first administration correlated with more incidence of fat necrosis.
However, the dosage of chemotherapy, number of days between NACT completion and
surgery, and number of circulating immune cells had no effect on post-operative
outcomes. Our report has the potential to inform the sequence of NACT administration,
thus reducing post- operative complication outcomes. This report also provides objective
data that can help counsel patients and delineate expectations for their immediate
autologous breast reconstruction. The benefit of taxane-first in improving tumor outcome
should be taken into consideration when making clinical decisions as this may outweigh
the risks of post-operative outcomes.
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